T cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.
Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
The European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the €250m EU circular bioeconomy fund.
https://european-biotechnology.com/wp-content/uploads/2024/04/european-investment-bank.jpg499750Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-12-02 09:02:072019-12-02 09:02:07European circular bioeconomy fund near closing
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-11-29_um_08.03.09.png305550Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-11-29 19:41:002019-11-29 19:41:00Researchers find new indication for cancer drug
Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.
https://european-biotechnology.com/wp-content/uploads/2024/04/20191127-maxivax.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-11-27 05:14:002019-11-27 05:14:00€7.34m for cancer vaccine developer
Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
https://european-biotechnology.com/wp-content/uploads/2024/04/Geneuro.jpg10001000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-11-26 05:14:002019-11-26 05:14:00GeNeuro and Karolinska Institute collaborate in multiple sclerosis
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-11-25 07:50:002019-11-25 07:50:00Arctoris: John Mattick on board
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
Big Pharma is cost driver of GAVI
Latest NewsMédecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine
ImCheck Therapeutics SAS raises €48m
Latest NewsT cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.
Pierre Fabre amends license agreement with Puma Biotechnology
Latest NewsPierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
European circular bioeconomy fund near closing
Latest NewsThe European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the €250m EU circular bioeconomy fund.
Researchers find new indication for cancer drug
Latest NewsFrench researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
Research team improves safety of LGMD2A gene therapy
Latest NewsResearchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.
€7.34m for cancer vaccine developer
Latest NewsHaving secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.
GeNeuro and Karolinska Institute collaborate in multiple sclerosis
Latest NewsGeneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
Arctoris: John Mattick on board
AppointmentsJohn Mattick has been appointed to the Board of Directors of Oxford-based research company Arctoris Ltd.
Tecentriq-Avastin combo hits endpoint in liver cancer
Latest NewsRoche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.